02031nas a2200289   4500008004100000022001400041245013300055210006900188260007300257300001200330490000900342520099500351653001501346653002601361653002601387653002101413653002201434653000901456653001501465100002201480700002201502700002501524700002101549700002401570700002701594856012001621       2007                        eng d  a0021-967300aEnantiomeric separation of novel anticancer agent 5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en- 1-one0 aEnantiomeric separation of novel anticancer agent 5hydroxy34meth  aPO BOX 211, 1000 AE AMSTERDAM, NETHERLANDSbELSEVIER SCIENCE BVcJAN  a184-1890 v11383 a<p>The enantiomers of 5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2-en- 1-one, a novel anticancer agent, were separated by derivatisation with caronaldehyde, separation of the resulting diastereoisomers of the corresponding esters by silica gel column chromatography and regeneration of alcohols (S)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2 -en-1-one and (R)5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2- en- 1-one under aqueous conditions. The absolute configuration of the enantiomers was determined by H-1 NMR studies of the corresponding Mosher esters. Alternatively, the enantiomers were separated by preparative HPLC to collect the (S)- and (R)-5-hydroxy-3-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)-cyclopent-2 -en-1-ones with high purity which was comparable with that obtained by the chemical method. The details of these methods have been presented herein. (c) 2006 Elsevier B.V. All rights reserved.</p>10aAnticancer10acolumn chromatography10adiaryl cyclopentenone10adiastereoisomers10aenantioseparation10aHPLC10aResolution1 aShinde, Popat, D.1 aJadhav, Vinod, H.1 aBorate, Hanumant, B.1 aBhide, Sunil, R.1 aSonawane, Kiran, B.1 aWakharkar, Radhika, D.  uhttps://library.ncl.res.in/content/enantiomeric-separation-novel-anticancer-agent-5-hydroxy-3-4-methoxyphenyl-2-34502802nas a2200241   4500008004100000022001400041245015300055210006900208260009000277300001400367490000700381520183700388653002602225653001302251653002402264100002202288700002902310700002502339700002402364700002402388700002702412856012102439       2014                        eng d  a1388-020900aIsolation, characterization and antihyperlipidemic activity of secoisolariciresinol diglucoside in poloxamer-407-induced experimental hyperlipidemia0 aIsolation characterization and antihyperlipidemic activity of se  aTELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDbINFORMA HEALTHCAREcSEP  a1094-11030 v523 a<p>Context: Linum usitatissimum L. (Linaceae), commonly known as flaxseed, is a good source of dietary fiber and lignans. Earlier we reported cardioprotective, antihyperlipidemic, and in vitro antioxidant activity of flax lignan concentrate (FLC) obtained from flaxseed. Objectives: To isolate secoisolariciresinol diglucoside (SDG) from FLC and to evaluate the antihyperlipidemic activity of SDG in poloxamer-407 (P-407)-induced hyperlipidaemic mice. Material and methods: FLC was subjected to column chromatography and further subjected to preparative HPTLC to isolate SDG. The chemical structure of the isolated compound was elucidated by UV, IR, H-1 NMR, C-13 NMR, DEPT, COSY, HSQC, HMBC, ROESY, MS, and specific optical rotation was recorded. Further, we have investigated the antihyperlipidaemic effect of SDG (20 mg/kg) in P-407-induced hyperlipidaemic rats. Hyperlipidaemia was induced by intraperitoneal administration of P-407 (30% w/v). Serum lipid parameters such as total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) levels were measured. Results and discussion: The structure and stereochemistry of the isolated compound were confirmed on the basis of 1D and 2D spectral data and characterized as SDG. Finally, isolated pure SDG was screened using a P-407-induced mice model for its antihyperlipidemic action using serum lipid parameters. The isolated SDG (20 mg/kg) significantly reduced serum cholesterol, triglyceride (p&lt;0.001), very low-density lipoprotein (p&lt;0.05), and non-significantly increased HDL-C. Conclusion: Finally, it was concluded unequivocally that SDG showed antihyperlipidaemic effects in P-407-induced hyperlipidaemic mice. Isolated pure SDG confirms that SDG is beneficial in the prevention of experimental hyperlipidemia in laboratory animals.</p>10acolumn chromatography10aflaxseed10aLinum usitatissimum1 aZanwar, Anand, A.1 aHegde, Mahabaleshwar, V.1 aRojatkar, Supada, R.1 aSonawane, Kiran, B.1 aRajamohanan, P., R.1 aBodhankar, Subhash, L.  uhttps://library.ncl.res.in/content/isolation-characterization-and-antihyperlipidemic-activity-secoisolariciresinol-0